Paul J. Lytle
2012
In 2012, Paul J. Lytle earned a total compensation of $666.7K as Chief Financial Officer at Peregrine Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $130,300 |
|---|---|
| Option Awards | $177,243 |
| Salary | $325,402 |
| Other | $33,784 |
| Total | $666,729 |
Lytle received $325.4K in salary, accounting for 49% of the total pay in 2012.
Lytle also received $130.3K in non-equity incentive plan, $177.2K in option awards and $33.8K in other compensation.
Rankings
In 2012, Paul J. Lytle's compensation ranked 7,746th out of 11,487 executives tracked by ExecPay. In other words, Lytle earned more than 32.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,746 out of 11,487 | 33rd |
Division Manufacturing | 2,787 out of 4,253 | 35th |
Major group Chemicals And Allied Products | 730 out of 1,203 | 39th |
Industry group Drugs | 517 out of 925 | 44th |
Industry Pharmaceutical Preparations | 407 out of 700 | 42nd |
Source: SEC filing on August 28, 2014.
Lytle's colleagues
We found four more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2012.
2012
Steven King
Peregrine Pharmaceuticals
Chief Executive Officer
2012
Jeffrey Masten
Peregrine Pharmaceuticals
Former Vice President, Quality
2012
Joseph Shan
Peregrine Pharmaceuticals
Vice President, Clinical & Regulatory Affairs
2012
Shelley Fussey
Peregrine Pharmaceuticals